Safety of rotigotine patch for ADPKD patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a skin patch called rotigotine to see if it is safe for people with ADPKD. It may help with blood pressure control, but you cannot have advanced kidney failure or certain other health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old and have ADPKD (autosomal dominant polycystic kidney disease).
- Your blood pressure must be well controlled (below 135/85 mmHg on average during the day).
- You cannot have advanced kidney failure (stage 4 or 5) or be on dialysis or have a kidney transplant.
- You cannot have had a heart attack or stroke in the past 6 months, or have severe liver disease.
- You must not have taken certain medications called dopamine agonists or antagonists in the last 6 months.
- You cannot have a history of addiction (gambling, alcohol over 20g/day, drug use) or be pregnant/breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new version of the rotigotine patch (a medicine given through the skin) sticks well and is safe compared to the already-approved Neupro patch. It might help people with Parkinson's who need a reliable way to take their medication.
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
This study tests whether a new skin patch, DM1001, is safe and how well the body tolerates it. It is for healthy adults who want to help find out if this patch could be used for future treatments.
Hear when a new Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.